Human IGFBP-7, His Tag (IG7-H5240) is expressed from human 293 cells (HEK293). It contains AA Asp 30 - Leu 282 (Accession # NP_001544).
Predicted N-terminus: His
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 27.0 kDa. The protein migrates as 35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human IGFBP-7, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Insulin-like growth factor-binding protein 7 (IGFBP7) is also known as IGFBP-rP1, MAC25 protein, PGI2-stimulating factor, prostacyclin-stimulating factor and tumor-derived adhesion factor, which contains one Ig-like C2-type (immunoglobulin-like) domain, one IGFBP N-terminal domain and one Kazal-like domain. The major function of IGFBP7 is the regulation of availability of insulin-like growth factors (IGFs) in tissue as well as in modulating IGF binding to its receptors. IGFBP7 binds to IGF with high affinity except for IGF-I and IGF-II.IGFBP7 also stimulates cell adhesion. Furthermore, IGFBP7 is implicated in some cancers.